Clinical Trials Logo

Bronchiolitis Obliterans clinical trials

View clinical trials related to Bronchiolitis Obliterans.

Filter by:

NCT ID: NCT00528853 Completed - Clinical trials for Bronchiolitis Obliterans Syndrome

Correlation of Lung Biopsy, BAL, and High Resolution CT Scan in Lung Transplantation

Start date: August 2007
Phase: N/A
Study type: Observational

A major source of graft failure and dysfunction in lung transplantation is known to be bronchiolitis obliterans (BO)and its clinical correlate called bronchiolitis obliterans syndrome(BOS). In fact, BOS is the leading cause of death in lung recipients beyond one year post transplant. Currently, our ability to assess lung injury after transplant is less than ideal. The purpose of this study is to use new computerized tomography(CT) technology, specifically , 64 bit acquisition, to detect and predict the onset of lung injuries, with the hope of finding better therapies that currently exist.

NCT ID: NCT00381147 Completed - Clinical trials for Bronchiolitis Obliterans

Use of Clarithromycin in Mustard-Induced Bronchiolitis

Start date: n/a
Phase: Phase 3
Study type: Interventional

We looked for the effectiveness of low-dose long-term prescription of clarithromycin in mustard-induced chronic pulmonary lesions, especially bronchiolitis obliterans

NCT ID: NCT00367419 Completed - Clinical trials for Bronchiolitis Obliterans

Use of Erythromycin in Mustard-Induced Bronchiolitis

Start date: n/a
Phase: Phase 4
Study type: Interventional

We looked for the effectiveness of low-dose long-term prescription of erythromycin in mustard-induced bronchiolitis obliterans

NCT ID: NCT00188825 Completed - COPD Clinical Trials

Study Comparing Simulect Plus Standard Immunosuppression to Standard Immunosuppression Alone for the Prevention of Acute Rejection and Bronchiolitis Obliterans in Lung Transplant

Start date: May 2004
Phase: Phase 3
Study type: Interventional

The study will evaluate the efficacy and safety of basiliximab Vs placebo as induction therapy combined with standard triple immunosuppression therapy, in the prevention of acute rejection episodes and prevention of Bronchiolitis Obliterans Syndrome.

NCT ID: NCT00141726 Completed - Clinical trials for Respiratory Distress Syndrome, Adult

Study of Enbrel (Etanercept) for the Treatment Sub-Acute Pulmonary Dysfunction After Allogeneic Stem Cell Transplant

Start date: October 2003
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the effectiveness of etanercept in the treatment of patients with sub-acute lung injury following a bone marrow transplant. This study will also examine the toxicity of treatment with etanercept as well as whether there is an improved quality of life in these patients.

NCT ID: NCT00029328 Completed - Pneumonia Clinical Trials

Etanercept for Non-Infectious Lung Injury Following Bone Marrow Transplantation

Start date: September 2001
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine the effects of etanercept, and define the toxicity, when administered to patients with acute non-infectious lung injury (idiopathic pneumonia syndrome, IPS) and with subacute pulmonary dysfunction after allogeneic stem cell transplantation.

NCT ID: NCT00027235 Completed - Clinical trials for Lung Diseases, Interstitial

Popcorn Lung: the Discovery of a New Disease

Start date: n/a
Phase: N/A
Study type: Observational

Recently, an epidemic of pulmonary disease has been recognized among workers in a popcorn factory in Jasper, Missouri. The exposure agent has not yet been identified, but suspects include butter flavoring and the powdered salt used in the mixing room. This disease resembles "Bronchiolitis Obliterans Syndrome", an illness that makes it difficult to breathe. Of the 117 workers studied, one year later, 25 subjects whom were working in the mixing room or in the microwave packaging area have had decreases in lung function seven times the norm for their age. Industrial hygiene experts revealed that dust concentrations of salt and other flavorings were much higher in the mixing room compared to the office and outdoor work areas. Recently, rats were exposed to vapors created by heating the butter flavor compound obtained from this plant. Six-hour exposure to vapors at very high concentration resulted in significant damage to the breathing apparatus. Thus, there is clinical, epidemiological, and animal toxicity data that appears to implicate some constituent present during the mixing of the butter flavoring, salt, and oil causing a form of obstructive airway disease that has been rapidly progressive in a number of workers. It is not clear what the pathophysiologic nature of this entity is, though it resembles Bronchiolitis Obliterans Syndrome. It is not known what the long term consequence of this will be on the active workers, nor is it clear whether preventive measures taken to reduce exposures in the mixing room and elsewhere in the plant are going to be effective.